KalVista Pharmaceuticals Inc
Company Profile
Business description
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Contact
55 Cambridge Parkway
Suite 901 East
CambridgeMA02142
USAT: +1 857 999-0075
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 April 2026
Employees
270
Stocks News & Analysis
stocks
Moated ASX player’s future growth prospects look solid
stocks
Ask the analyst: Can this genius product create the next ASX software king?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,030.90 | 91.60 | -1.00% |
| CAC 40 | 7,881.96 | 94.98 | 1.22% |
| DAX 40 | 23,668.14 | 308.96 | 1.32% |
| Dow JONES (US) | 46,018.32 | 260.42 | 0.57% |
| FTSE 100 | 9,242.28 | 46.62 | 0.51% |
| HKSE | 26,544.85 | 106.34 | 0.40% |
| NASDAQ | 22,261.33 | 72.63 | -0.33% |
| Nikkei 225 | 45,303.43 | 401.16 | 0.89% |
| NZX 50 Index | 13,120.03 | 114.86 | -0.87% |
| S&P 500 | 6,600.35 | 6.41 | -0.10% |
| S&P/ASX 200 | 8,745.20 | 103.30 | -1.17% |
| SSE Composite Index | 3,831.66 | 44.68 | -1.15% |